Hepatocellular carcinoma (HCC) is a major cause of death in many countries, including South Korea. To provide useful and sensible advice for clinical management of patients with HCC, the Korean Liver Cancer Association and National Cancer Center Korea Practice Guideline Revision Committee have recently revised the practice guidelines for HCC management. However, there are some differences between practice guidelines and real-life clinical practice. In this review, we describe some key recommendations of the 2022 version of practice guidelines and the real-life clinical situation in South Korea, together with discussion about efforts needed to reduce the difference between guidelines and real-life clinical practice.
Citations
Citations to this article as recorded by
Neutrophil count predicts the complete response after transarterial chemoembolization related to favorable outcome in hepatocellular carcinoma Young Mi Hong European Journal of Gastroenterology & Hepatology.2025; 37(1): 94. CrossRef
Epidemiological characteristics and precise prophylaxis and control of HBV-associated primary liver cancer Yuqi Feng, Letian Fang, Guangwen Cao Hepatoma Research.2025;[Epub] CrossRef
A Prospective, Multicenter, Randomized, Noninferiority Trial of Stopad® Versus Tachosil® for Hemostasis After Liver Resection Seung Yeon Lim, Gi Hong Choi, Jin Hong Lim, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Boram Lee, Yeshong Park, MeeYoung Kang, Jinju Kim, Hyelim Joo, Jai Young Cho Cancers.2025; 17(5): 757. CrossRef
Reply: Intrahepatic IgA complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma Deok Hwa Seo, Pil Soo Sung Hepatology.2025; 81(4): E123. CrossRef
The Association Between Hepatocellular Carcinoma and Gastrointestinal Adenocarcinoma: Is This a New Syndrome in Patients With Cirrhosis? A Case Series Fabrizio Bronte, Fabio D'Amato, Maria Rosa Barcellona, Giuseppe Bronte, Giuseppe Malizia, Salvatore Ialuna, Giorgio Fusco, Francesco Verderame, Enrico Bronte, Maria Grazia Bavetta Cancer Reports.2025;[Epub] CrossRef
Roadmap for HCC Surveillance and Management in the Asia Pacific Masatoshi Kudo, Bui Thi Oanh, Chien-Jen Chen, Do Thi Ngat, Jacob George, Do Young Kim, Luckxawan Pimsawadi, Pisit Tangkijvanich, Raoh-Fang Pwu, Rosmawati Mohamed, Sakarn Bunnag, Sheng-Nan Lu, Sirintip Kudtiyakarn, Tatsuya Kanto, Teerha Piratvisuth, Chao-C Cancers.2025; 17(12): 1928. CrossRef
TCR-based cellular immunotherapy for hepatocellular carcinoma: advances, challenges, and prospects Wanting Zeng, Wei Zhu, Guosheng Yuan, Jinzhang Chen, Zhanhui Wang, Jinlin Hou, De-Ke Jiang Cancer Immunology, Immunotherapy.2025;[Epub] CrossRef
Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab–bevacizumab Heechul Nam, Dong Yun Kim, Do Young Kim, Ji Hoon Kim, Chang Wook Kim, Jaejun Lee, Keungmo Yang, Ji Won Han, Pil Soo Sung, Seung Kew Yoon, Hee Sun Cho, Hyun Yang, Si Hyun Bae, Soon Kyu Lee, Jung Hyun Kwon, Soon Woo Nam, Ahlim Lee, Do Seon Song, U Im Chang, Hepatology.2025;[Epub] CrossRef
Subset of Child-Pugh Score 7 Shows Comparable Survival Outcomes to Child-Pugh Score 6 in Patients with Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab Jaejun Lee, Keungmo Yang, Ji Won Han, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Hee Sun Cho, Hyun Yang, Si Hyun Bae, Ji Hoon Kim, Heechul Nam, Chang Wook Kim, Hae Lim Lee, Hee Yeon Kim, Sung Won Lee, Ahlim Lee, Do Seon Song, Myeong Jun Song, Soon Woo Clinical Cancer Research.2025; 31(20): 4323. CrossRef
Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion: An Inverse Probability of Treatment Weighted Analysis Jihoon Kim, Jin-Hyoung Kim, Byung Soo Im, Gun Ha Kim, Hee Ho Chu, Dong Il Gwon, Ji Hoon Shin, Ju Hyun Shim, Sang Min Yoon, Sehee Kim Cancers.2025; 18(1): 33. CrossRef
The Position of Multikinase Inhibitors in the Era of Immune-Checkpoint Inhibitors for Hepatocellular Carcinoma Beom Kyung Kim Gut and Liver.2024; 18(1): 3. CrossRef
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma Josep M. Llovet, Roser Pinyol, Mark Yarchoan, Amit G. Singal, Thomas U. Marron, Myron Schwartz, Eli Pikarsky, Masatoshi Kudo, Richard S. Finn Nature Reviews Clinical Oncology.2024; 21(4): 294. CrossRef
High‐dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study Jun Sik Yoon, Ji Hoon Hong, Soo Young Park, Seung Up Kim, Hwi Young Kim, Ju Yeon Kim, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Han Ah Lee, Gi‐Ae Kim, Dong Hyun Sinn, Sung Jae Park, Youn Jae Lee, Yoon Jun Kim, Jung‐Hwan Yoon, Jeong‐Hoon Lee Alimentary Pharmacology & Therapeutics.2024; 59(8): 973. CrossRef
Role of reimbursement and Physicians' awareness in the survival of sorafenib‐eligible advanced hepatocellular carcinoma patients Hui‐Ling Huang, Te‐Sheng Chang, Lariza Marie Canseco, Fan Wu, Sheng‐Nan Lu The Kaohsiung Journal of Medical Sciences.2024; 40(6): 589. CrossRef
Limited Generalizability of Retrospective Single-Center Cohort Study in Comparison to Multicenter Cohort Study on Prognosis of Hepatocellular Carcinoma Ye Rim Kim, Sung Won Chung, Min-Ju Kim, Won-Mook Choi, Jonggi Choi, Danbi Lee, Han Chu Lee, Ju Hyun Shim Journal of Hepatocellular Carcinoma.2024; Volume 11: 1235. CrossRef
Similar recurrence after curative treatment of HBV-related HCC, regardless of HBV replication activity Mi Na Kim, Beom Kyung Kim, Heejin Cho, Myung Ji Goh, Yun Ho Roh, Su Jong Yu, Dong Hyun Sinn, Soo Young Park, Seung Up Kim, Tyng-Yuan Jang PLOS ONE.2024; 19(8): e0307712. CrossRef
The position of loco-regional therapy in the management of hepatocellular carcinoma with extrahepatic metastases Beom Kyung Kim Journal of Liver Cancer.2024; 24(2): 129. CrossRef
Role of transarterial chemoembolization for hepatocellular carcinoma with extrahepatic metastases in the era of advancing systemic therapy Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Moon Seok Choi Journal of Liver Cancer.2024; 24(2): 243. CrossRef
Primary treatments for solitary hepatocellular carcinoma ≤ 3 cm: A systematic review and network meta-analysis Sang-Hoon Kim, Ki-Hun Kim, Byeong-Gon Na, Sung Min Kim, Rak-Kyun Oh Annals of Hepato-Biliary-Pancreatic Surgery.2024; 28(4): 397. CrossRef
Evolution of Liver Resection for Hepatocellular Carcinoma: Change Point Analysis of Textbook Outcome over Twenty Years Yeshong Park, Ho-Seong Han, Seung Yeon Lim, Hyelim Joo, Jinju Kim, MeeYoung Kang, Boram Lee, Hae Won Lee, Yoo-Seok Yoon, Jai Young Cho Medicina.2024; 61(1): 12. CrossRef
A Real-World Comparative Analysis of Atezolizumab Plus Bevacizumab and Transarterial Chemoembolization Plus Radiotherapy in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis Soon Kyu Lee, Jung Hyun Kwon, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Ji Hoon Kim, Ahlim Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo Su Cancers.2023; 15(17): 4423. CrossRef
What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea? Min Kyung Park, Yoon Jun Kim Clinical and Molecular Hepatology.2023; 29(2): 332. CrossRef
The current trends in the health burden of primary liver cancer across the globe Peter Konyn, Aijaz Ahmed, Donghee Kim Clinical and Molecular Hepatology.2023; 29(2): 358. CrossRef
Toward user-friendly and evidence-based practice guidelines for hepatocellular carcinoma Do Young Kim Clinical and Molecular Hepatology.2023; 29(2): 335. CrossRef
A Phase I/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma Yun Bin Lee, Joon Yeul Nam, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Hyo-Cheol Kim, Jin Chul Paeng, Jung-Hwan Yoon, Yoon Jun Kim Clinical Cancer Research.2023; 29(18): 3650. CrossRef
Tips for Preparing and Practicing Thermal Ablation Therapy of Hepatocellular Carcinoma Yasunori Minami, Tomoko Aoki, Satoru Hagiwara, Masatoshi Kudo Cancers.2023; 15(19): 4763. CrossRef
Liver transplantation (LT) is one of the most effective treatments for hepatocellular carcinoma (HCC). Although LT eliminates HCC and greatly reduces recurrence, some patients experience recurrence after LT. Criteria and models for screening patients with a high probability of HCC recurrence after LT, starting with the Milan criteria, have been published. These models have changed over time, but a standard has not been established. We summarized HCC prediction models after LT by focusing on the application of radiologic, serologic, and pathologic factors and recent trends. This review will look at studies that are based on living donor LT and deceased donor LT, as well as studies that downstaging procedures have been performed preoperatively. This ultimately aims to help make decisions for evaluating the HCC state and selecting candidates for LT according to the circumstances of each transplantation center.
Citations
Citations to this article as recorded by
Lack of progress in cancer-related outcomes after liver transplantation: Mitigating risk and identifying future needs to move this needle Alex Liu, Wei Rao, Kymberly D. Watt Liver Transplantation.2026; 32(1): 107. CrossRef
Comparative Validation of Prediction Models for HCC Outcomes in Living Donor Liver Transplantation: Superiority of Tumor Markers to Imaging Study Hwa‐Hee Koh, Minyu Kang, Deok‐Gie Kim, Jae Hyon Park, Eun‐Ki Min, Jae Geun Lee, Myoung Soo Kim, Dong Jin Joo Journal of Gastroenterology and Hepatology.2025; 40(3): 626. CrossRef
Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation Meng Sha, Jun Wang, Jie Cao, Zhi-Hui Zou, Xiao-ye Qu, Zhi-feng Xi, Chuan Shen, Ying Tong, Jian-jun Zhang, Seogsong Jeong, Qiang Xia Clinical and Molecular Hepatology.2025; 31(Suppl): S285. CrossRef
α-Fetoprotein model versus Milan criteria in predicting outcomes after hepatic resection for hepatocellular carcinoma: multicentre study Chao Li, Yong-Kang Diao, Yi-Fan Li, Shao-Dong Lv, Xian-Ming Wang, Xue-Dong Wang, Qi-Xuan Zheng, Hong Wang, Han Liu, Kong-Ying Lin, Ying-Jian Liang, Ya-Hao Zhou, Wei-Min Gu, Ming-Da Wang, Lan-Qing Yao, Xin-Fei Xu, Jia-Hao Xu, Li-Hui Gu, Timothy M Pawlik, F BJS Open.2025;[Epub] CrossRef
Comparison of initial treatments for resectable hepatocellular carcinoma within Milan criteria: an observational study based on a nationwide survey Sang Jin Kim, Woo Kyoung Jeong, Hyung-Joon Han, Gyu-Seong Choi, Kyun-Hwan Kim, Jongman Kim Annals of Surgical Treatment and Research.2025; 108(5): 279. CrossRef
Traditional herbal medicine as an adjuvant therapy for preventing the recurrence of hepatocellular carcinoma after radical resection: Development and validation of a machine learning prediction model Xinyu Yue, Meihuan Fu, Song Yu, Huayue Shi, Simo Cheng, Xiaofeng Zhai European Journal of Integrative Medicine.2025; 78: 102535. CrossRef
Experimental and Clinical Transplantation.2025;[Epub] CrossRef
Integrating Alpha‐Fetoprotein and Protein Induced by Vitamin K Antagonist‐II as Surveillance Tools After Liver Transplantation for Hepatocellular Carcinoma: A Novel Protocol for Early Detection of Tumor Recurrence Jiyoung Kim, Kwang‐Woong Lee, Jae‐Yoon Kim, Jaewon Lee, Hyun Hwa Choi, Su young Hong, Jeong‐Moo Lee, Suk Kyun Hong, YoungRok Choi, Nam‐Joon Yi, Kyung‐Suk Suh Clinical Transplantation.2025;[Epub] CrossRef
A non-invasive decision tree predicting recurrence-free survival after liver transplantation for hepatocellular carcinoma Mo-Dan Yang, Jian-Yong Zhuo, Guo-Ying Wang, Li Zhuang, Xiao Xu, Shu-Sen Zheng, Yang Yang, Di Lu Hepatobiliary & Pancreatic Diseases International.2025;[Epub] CrossRef
Activating transcription factor 4-mediated upregulation of Heat Shock Protein Family A Member 4 promotes hepatocellular carcinoma progression through activation of Wnt/β-catenin/EMT signaling pathway Ruixi Li, Kunnan Wang, Naijing Hou, Yu Tian, Biyan Gong, Min Tang International Journal of Biological Macromolecules.2025; 333: 148850. CrossRef
Mesenchymal Stem Cell-Mediated Targeted Drug Delivery Systems for Hepatocellular Carcinoma: Current Advances and Future Directions Yang Gao, Jian-Ping Wang, De-Fei Hong, Chang Yang, Hua Naranmandura Bioengineering.2025; 12(11): 1206. CrossRef
Prognostic significance of MRI features in patients with solitary large hepatocellular carcinoma following surgical resection Kyowon Gu, Ji Hye Min, Jeong Hyun Lee, Jaeseung Shin, Woo Kyoung Jeong, Young Kon Kim, Honsoul Kim, Sun-Young Baek, Jong Man Kim, Gyu Seong Choi, Jinsoo Rhu, Sang Yun Ha European Radiology.2024; 34(11): 7002. CrossRef
From prediction to prevention: Machine learning revolutionizes hepatocellular carcinoma recurrence monitoring Mariana Michelle Ramírez-Mejía, Nahum Méndez-Sánchez World Journal of Gastroenterology.2024; 30(7): 631. CrossRef
Risk assessment in liver transplantation for hepatocellular carcinoma: long-term follow-up of a two-centre experience Chase J. Wehrle, Roma Raj, Marianna Maspero, Sangeeta Satish, Bijan Eghtesad, Alejandro Pita, Jaekeun Kim, Mazhar Khalil, Esteban Calderon, Danny Orabi, Bobby Zervos, Jamak Modaresi Esfeh, Maureen Whitsett Linganna, Teresa Diago-Uso, Masato Fujiki, Cristi International Journal of Surgery.2024; 110(5): 2818. CrossRef
Challenges related to clinical decision-making in hepatocellular carcinoma recurrence post-liver transplantation: Is there a hope? Nourhan Badwei World Journal of Transplantation.2024;[Epub] CrossRef
Advances in Understanding Hepatocellular Carcinoma Vasculature: Implications for Diagnosis, Prognostication, and Treatment Hyungjin Rhee, Young Nyun Park, Jin-Young Choi Korean Journal of Radiology.2024; 25(10): 887. CrossRef
An inflammatory liquid fingerprint predicting tumor recurrence after liver transplantation for hepatocellular carcinoma Modan Yang, Zuyuan Lin, Li Zhuang, Linhui Pan, Rui Wang, Hao Chen, Zhihang Hu, Wei Shen, Jianyong Zhuo, Xinyu Yang, Huigang Li, Chiyu He, Zhe Yang, Qinfen Xie, Siyi Dong, Junli Chen, Renyi Su, Xuyong Wei, Junjie Yin, Shusen Zheng, Di Lu, Xiao Xu MedComm.2024;[Epub] CrossRef
New prognostic model for liver transplantation outcomes in hepatocellular carcinoma S. E. Voskanyan, V. S. Rudakov, A. I. Sushkov, M. V. Popov, A. N. Bashkov, K. K. Gubarev, A. I. Artemyev, I. Yu. Kolyshev, M. Muktazhan, A. N. Pashkov, E. V. Naydenov, D. S. Svetlakova Transplantologiya. The Russian Journal of Transplantation.2024; 16(3): 278. CrossRef
Chitinase-3 like-protein-1, a prognostic biomarker in patients with hepatocellular carcinoma and concomitant myosteatosis Chiyu He, Zhihang Hu, Zuyuan Lin, Hao Chen, Chenghao Cao, Jinyan Chen, Xudong Yang, Huigang Li, Wei Shen, Xuyong Wei, Li Zhuang, Shusen Zheng, Xiao Xu, Di Lu BMC Cancer.2024;[Epub] CrossRef
Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis: Editorial on “Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging” Abdelrahman M Attia, Hasmik Adetyan, Ju Dong Yang Clinical and Molecular Hepatology.2024; 30(4): 653. CrossRef
Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation Jianming Yang, Yewu Chen, Haobin Sun, Xijian Zhang, Jianfeng Wang, Zhixing Liang, Binsheng Fu, Tong Zhang, Shuhong Yi, Yinan Deng, Yang Yang Infectious Agents and Cancer.2023;[Epub] CrossRef
Molecular Clues for Prediction of Hepatocellular Carcinoma Recurrence After Liver Transplantation Nourhan Badwei Journal of Clinical and Experimental Hepatology.2023; 13(5): 804. CrossRef
Persistently Elevated HBV Viral-Host Junction DNA in Urine as a Biomarker for Hepatocellular Carcinoma Minimum Residual Disease and Recurrence: A Pilot Study Selena Y. Lin, Dina Halegoua-DeMarzio, Peter Block, Yu-Lan Kao, Jesse Civan, Fwu-Shan Shieh, Wei Song, Hie-Won Hann, Ying-Hsiu Su Diagnostics.2023; 13(9): 1537. CrossRef
Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging Yoon Jung Hwang, Jae Seok Bae, Youngeun Lee, Bo Yun Hur, Dong Ho Lee, Haeryoung Kim Clinical and Molecular Hepatology.2023; 29(3): 733. CrossRef
Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients Xiaoning Wu, Xiaoqian Xu, Jialing Zhou, Yameng Sun, Huiguo Ding, Wen Xie, Guofeng Chen, Anlin Ma, HongXin Piao, Bingqiong Wang, Shuyan Chen, Tongtong Meng, Xiaojuan Ou, Hwai-I Yang, Jidong Jia, Yuanyuan Kong, Hong You Clinical and Molecular Hepatology.2023; 29(3): 747. CrossRef
Sequential regorafenib or nivolumab therapy in recurrent hepatocellular carcinoma with sorafenib failure in liver transplant patients does not improve prognosis Jieun Kwon, Jongman Kim, Jinsoo Rhu, Gyu-Seong Choi, Jae-Won Joh Annals of Liver Transplantation.2023; 3(2): 104. CrossRef
Neutrophil extracellular traps and complications of liver transplantation Yanyao Liu, Ping Yan, Yue Bin, Xiaoyan Qin, Zhongjun Wu Frontiers in Immunology.2022;[Epub] CrossRef
Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Satohiro Masuda, Florian Lemaitre, Markus J. Barten, Stein Bergan, Maria Shipkova, Teun van Gelder, Sander Vinks, Eberhard Wieland, Kirsten Bornemann-Kolatzki, Mercè Brunet, Brenda de Winter, Maja-Theresa Dieterlen, Laure Elens, Taihei Ito, Kamisha Johnso Therapeutic Drug Monitoring.2025; 47(1): 4. CrossRef
Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation Ji Won Han, Jong Young Choi, Eun Sun Jung, Ji Hoon Kim, Hee Sun Cho, Jae-Sung Yoo, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Ho Joong Choi, Young Kyoung You World Journal of Gastrointestinal Surgery.2023; 15(12): 2727. CrossRef
Optimal imaging criteria and modality to determine Milan criteria for the prediction of post-transplant HCC recurrence after locoregional treatment Nieun Seo, Dong Jin Joo, Mi-Suk Park, Seung-seob Kim, Hye Jung Shin, Yong Eun Chung, Jin-Young Choi, Myoung Soo Kim, Myeong-Jin Kim European Radiology.2022; 33(1): 501. CrossRef
Background/Aims Hepatitis B core antibody (anti-HBc)-positive donors are used as an extended donor pool, and current guidelines recommend the usage of nucleos(t)ide analogues (NAs) as prophylaxis for preventing de novo hepatitis B virus infection (DNH). We analyzed the long-term outcomes of a large cohort of liver transplantation (LT) patients receiving anti-HBc-positive grafts and evaluated the risk of DNH when hepatitis B immunoglobulin (HBIG) monotherapy was used as prophylaxis. We also compared the cost-effectiveness of HBIG and NAs.
Methods We retrospectively reviewed 457 patients with anti-HBc-positive grafts and 898 patients with anti-HBc-negative grafts who underwent LT between January 2001 and December 2018. We compared recipient characteristics according to the anti-HBc status of the donor, and compared the costs of using NAs for the rest of the patient’s life and using HBIG to maintain hepatitis B surface antibody titers above 200 IU/L.
Results The 1-, 5-, and 10-year patient survival rates were 87.7%, 73.5%, and 67.7%, respectively, in patients with anti-HBc-positive grafts, and 88.5%, 77.4%, and 70.3%, respectively, in patients with anti-HBc-negative grafts (P=0.113). Among 457 recipients with anti-HBc-positive grafts, 117 (25.6%) were non-HBV recipients. The overall incidence of DNH was 0.9%. When using HBIG under insurance coverage, the cumulative cost was lower compared with using NA continuously without insurance coverage in Korea.
Conclusions Anti-HBc-positive grafts alone do not affect patient survival or graft survival. HBIG monoprophylaxis has good outcomes for preventing DNH, and the patient’s long-term cost burden is low in Korea because of the national insurance system in this cohort.
Citations
Citations to this article as recorded by
Management of Hepatitis B virus infection in patients on treatment with immunosuppressants or immunomodulators: Position Paper of Associazione Italiana Studio del Fegato (AISF), Associazione Italiana di Oncologia Medica (AIOM), Gruppo Italiano per il Trap Mauro Viganò, Roberta D’Ambrosio, Ciro Celsa, Agostino Colli, Nicola Coppola, Bruno Daniele, Elisabetta Degasperi, Gianpiero D’Offizi, Vito Di Marco, Stefano Fagiuoli, Martina Gambato, Corrado Girmenia, Paolo Grossi, Pietro Lampertico, Andrea Lauterio, Ma Digestive and Liver Disease.2025; 57(12): 2257. CrossRef
Clinical Significance and Remaining Issues of Anti-HBc Antibody and HBV Core-Related Antigen Yoshihiko Yano, Itsuko Sato, Takamitsu Imanishi, Ryutaro Yoshida, Takanori Matsuura, Yoshihide Ueda, Yuzo Kodama Diagnostics.2024; 14(7): 728. CrossRef
Survival after liver transplantation from hepatitis B-core positive donors at a quaternary care hospital in Brazil Fabiana Siroma, Edson Abdala, Stefanie Lima do Nascimento Castro, Wellington Andraus, Luiz Augusto Carneiro D´Álbuquerque, Alice Tung Wan Song The Brazilian Journal of Infectious Diseases.2024; 28(6): 104384. CrossRef
Long-term outcomes of active vaccination against de novo hepatitis B among pediatric recipients of living donor liver transplantations with anti-HBc (+) grafts: a retrospective case–control study Chee-Chien Yong, Yu-Hung Lin, Wendell Z. Espinosa, I-Hsuan Chen, Shih-Ho Wang, Yi-Chia Chan, Chao-Long Chen, Chih-Che Lin International Journal of Surgery.2024; 110(10): 6702. CrossRef
Cost-effectiveness of Kidney Transplantation From Donors at Increased Risk of Blood-borne Virus Infection Transmission Karan K. Shah, Melanie Wyld, James A. Hedley, Karen M.J. Waller, Nicole De La Mata, Angela C. Webster, Rachael L. Morton Transplantation.2023; 107(9): 2028. CrossRef
Jong Man Kim, Deok Gie Kim, Jihyun Kim, Keunsung Lee, Kwang-Woong Lee, Je Ho Ryu, Bong-Wan Kim, Dong Lak Choi, Young Kyoung You, Dong-Sik Kim, Yang Won Nah, Koo Jeong Kang, Jai Young Cho, Geun Hong, Hee Chul Yu, Ju Ik Moon, Dongho Choi, Shin Hwang, Myoung Soo Kim
Clin Mol Hepatol 2021;27(3):451-462. Published online February 2, 2021
Background/Aims To analyze the incidence and risk factors of outcomes after liver transplantation (LT) in the Korean population.
Methods This study analyzed data from the liver cohort of Korean Organ Transplantation Registry (KOTRY) who had LT between May 2014 and December 2017. Study measures included the incidence of post-LT outcomes in recipients of living donor LT (LDLT) and deceased donor LT (DDLT). Cox multivariate proportional hazards model was used to determine the potential risk factors predicting the outcomes.
Results A total of 2,563 adult recipients with LT (LDLT, n=1,956; DDLT, n=607) were included, with mean±standard deviation age of 53.9±8.9 years, and 72.2% were male. The post-LT outcomes observed in each LDLT and DDLT recipients were death (4.0% and 14.7%), graft loss (5.0% and 16.1%), rejection (7.0% and 12.0%), renal failure (2.7% and 13.8%), new onset of diabetes (12.5% and 15.4%), and hepatocellular carcinoma (HCC) recurrence (both 6.7%). In both LDLT and DDLT recipients, the most common post-LT complications were renal dysfunction (33.6% and 51.4%), infection (26.7% and 48.4%), and surgical complication (22.5% and 23.9%). Incidence of these outcomes were generally higher among recipients of DDLT than LDLT. Multivariate analysis indicated recipient age and DDLT as significant risk factors associated with death and graft loss. DDLT and ABO incompatible transplant were prognostic factors for rejection, and HCC beyond Milan criteria at pre-transplant was a strong predictor of HCC recurrence.
Conclusions This study is a good indicator of the post-LT prognosis in the Korean population and suggests a significant burden of post-LT complications.
Citations
Citations to this article as recorded by
Outcomes of living-donor liver transplantation in older patients over 65 and 70 years compared to the younger recipients Deok-Gie Kim, Young Jin Yoo, Minyu Kang, Hwa-hee Koh, Eun-Ki Min, Jae Geun Lee, Myoung Soo Kim, Dong Jin Joo Asian Journal of Surgery.2026; 49(1): 76. CrossRef
Temporal evolution of living donor liver transplantation survival—A United Network for Organ Sharing registry study Christian T.J. Magyar, Zhihao Li, Laia Aceituno, Marco P.A.W. Claasen, Tommy Ivanics, Woo Jin Choi, Luckshi Rajendran, Blayne A. Sayed, Roxana Bucur, Nadia Rukavina, Nazia Selzner, Anand Ghanekar, Mark Cattral, Gonzalo Sapisochin American Journal of Transplantation.2025; 25(2): 406. CrossRef
Impact of Chronic Hepatitis C Virus on Acute Kidney Injury After Living Donor Liver Transplantation Jae Hwan Kim, Kyoung-Sun Kim, Hye-Mee Kwon, Sung-Hoon Kim, In-Gu Jun, Jun-Gol Song, Gyu-Sam Hwang Anesthesia & Analgesia.2025; 141(3): 608. CrossRef
Preoperative Factors Affecting Graft Survival After ABO-incompatible Adult Liver Transplantation Hyun-Jun Nam, Deok-Gie Kim, Eun-Ki Min, Jae Geun Lee, Dai Hoon Han, Sinyoung Kim, Kyung-A Lee, Gi Hong Choi, Dong Jin Joo, Hyun Ok Kim, Soon Sung Kwon, Myoung Soo Kim Transplantation.2025; 109(3): e157. CrossRef
Association of primary hepatocellular carcinoma laterality with oncological outcomes for hepatic resection patients: A retrospective, multicenter, propensity score-matched study Okjoo Lee, Jaehong Jeong, So Kyung Yoon, Jun Chul Chung, Jongman Kim, Kwang-Woong Lee, Hyung Chul Kim Asian Journal of Surgery.2025; 48(4): 2241. CrossRef
Intrapatient variability of tacrolimus trough level may be not the cause, but an indirect parameter of comorbidities: Editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development foll Jongman Kim Clinical and Molecular Hepatology.2025; 31(2): 589. CrossRef
Emergency living donor liver transplantation Jongman Kim Annals of Liver Transplantation.2025; 5(1): 27. CrossRef
Safety and Therapeutic Outcomes of Adjuvant Immunotherapy With Autologous Cytokine-induced Killer Cells for Patients With Hepatocellular Carcinoma Beyond Milan Criteria After Liver Transplantation Geun Hong, Dong Kyu Han, Jinsoo Rhu, Suk Kyun Hong, YoungRok Choi, Nam-Joon Yi, Kwang-Woong Lee, Jongman Kim, Jaeseok Yang, Kyung-Suk Suh Transplantation.2025; 109(10): e596. CrossRef
Meta‐Analysis: Comparison of Living Versus Deceased Liver Transplantation for Primary Sclerosing Cholangitis Ana Beatriz Afonso, Carolina Morais da Silva, Paulo Nogueira, Mariana Verdelho Machado Alimentary Pharmacology & Therapeutics.2025; 62(8): 768. CrossRef
Integrating Alpha‐Fetoprotein and Protein Induced by Vitamin K Antagonist‐II as Surveillance Tools After Liver Transplantation for Hepatocellular Carcinoma: A Novel Protocol for Early Detection of Tumor Recurrence Jiyoung Kim, Kwang‐Woong Lee, Jae‐Yoon Kim, Jaewon Lee, Hyun Hwa Choi, Su young Hong, Jeong‐Moo Lee, Suk Kyun Hong, YoungRok Choi, Nam‐Joon Yi, Kyung‐Suk Suh Clinical Transplantation.2025;[Epub] CrossRef
The evaluation of inflammatory and immune composite markers for complications after deceased donor liver transplantation – a retrospective cohort study Zhihong Zheng, Shuman Kuang, Zipei Wang, Jin Gu, Jichang Jiang, Zhou Yu, Lijin Zhao Annals of Medicine.2025;[Epub] CrossRef
Machine Learning–Based Selection of Resection vs Transplant and Survival in Hepatocellular Carcinoma Hyun Uk Kim, Ji Won Han, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Ho Joong Choi, Young Kyoung You JAMA Network Open.2025; 8(9): e2532353. CrossRef
Living versus deceased donor liver transplantation in highly urgent patients using Korean national data Jongman Kim, Sang Jin Kim, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung Annals of Liver Transplantation.2025; 5(2): 115. CrossRef
Predicting risk factors for waiting mortality in adult emergent living donor liver transplantation based on Korean national data Sang Jin Kim, Jongman Kim, Kyunga Kim, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung Annals of Liver Transplantation.2025; 5(2): 107. CrossRef
Liver Transplantation for Hepatocellular Carcinoma: A Comprehensive Review Seok-Hwan Kim Convergence Hepatology.2025; 1(1): 24. CrossRef
Causes of death and associated factors with death after liver transplantation: a nationwide database study Junghyun Yoon, Hanjoon Kim, Dongho Choi, Boyoung Park HPB.2024; 26(1): 54. CrossRef
Clinical impact and risk factors for cytomegalovirus infection in deceased donor liver transplantation without prophylaxis: Single center experience Deok-Gie Kim, Eun-Ki Min, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim Annals of Liver Transplantation.2024; 4(1): 23. CrossRef
Recurrence risk prediction models for hepatocellular carcinoma after liver transplantation Xu Zhang, Chi Chen, Yan Wang, Jun Xu Journal of Gastroenterology and Hepatology.2024; 39(11): 2272. CrossRef
Chitinase-3 like-protein-1, a prognostic biomarker in patients with hepatocellular carcinoma and concomitant myosteatosis Chiyu He, Zhihang Hu, Zuyuan Lin, Hao Chen, Chenghao Cao, Jinyan Chen, Xudong Yang, Huigang Li, Wei Shen, Xuyong Wei, Li Zhuang, Shusen Zheng, Xiao Xu, Di Lu BMC Cancer.2024;[Epub] CrossRef
Mortality and associated factors among patients who underwent liver transplantation in South Korea from 2017 to 2021: a retrospective observational study Tak Kyu Oh, In-Ae Song Annals of Surgical Treatment and Research.2024; 107(5): 245. CrossRef
Effects of combined immunosuppressant and hepatitis B virus antiviral use on COVID-19 vaccination in recipients of living donor liver transplantation Ryunjin Lee, Jiwan Choi, Eunkyeong Lee, Jooyoung Lee, Jiye Kim, Seoon Kang, Hye-In An, Sung-Han Kim, Sung-Min Kim, Eun-Kyoung Jwa, Gil-Chun Park, Jung-Man Namgoong, Gi-Won Song, Young-In Yoon, Eunyoung Tak, Sung-Gyu Lee PeerJ.2024; 12: e18651. CrossRef
Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim European Journal of Internal Medicine.2023; 107: 66. CrossRef
Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study Byungyoon Yun, Juyeon Oh, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim American Journal of Gastroenterology.2023; 118(6): 1001. CrossRef
Physical Performance Decline During the Early Posttransplantation Period Affects Survival After Living Donor Liver Transplantation Deok-Gie Kim, Shin Hwang, Kwang-Woong Lee, Gyu-seong Choi, Young Kyoung You, Je Ho Ryu, Bong-Wan Kim, Yang Won Nah, Dong-Sik Kim, Jai Young Cho, Koo Jeong Kang, Geun Hong, Hee Chul Yu, Man ki Ju, Suk-Won Suh, Kwan Woo Kim, Dongho Choi, Jaehong Jeong, Soo Transplantation.2023; 107(7): 1545. CrossRef
Validation of the Model for End-Stage Liver Disease 3.0 in Korean Patients on the Liver Transplant Waiting List Jiwon Yang, Jung-Bin Park, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Jonggi Choi Clinical Gastroenterology and Hepatology.2023; 21(13): 3437. CrossRef
Incidence, mortality, and risk factors associated with carbapenem‐resistant Acinetobacter baumannii bacteremia within 30 days after liver transplantation Eun‐Ki Min, Seung Hyuk Yim, Mun Chae Choi, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim, Deok‐Gie Kim Clinical Transplantation.2023;[Epub] CrossRef
Risk Factors for Cytomegalovirus Infection and Its Impact on Survival after Living Donor Liver Transplantation in South Korea: A Nested Case-Control Study Seung Hyuk Yim, Mun Chae Choi, Deok-Gie Kim, Eun-Ki Min, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim Pathogens.2023; 12(4): 521. CrossRef
Impact of institutional case volume of solid organ transplantation on patient outcomes and implications for healthcare policy in Korea Christine Kang, Ho Geol Ryu Korean Journal of Transplantation.2023; 37(1): 1. CrossRef
Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy Beom Kyung Kim, Sang Hoon Ahn Journal of the Formosan Medical Association.2023; 122(12): 1238. CrossRef
Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis Fernanda Onofrio, Katina Zheng, Cherry Xu, Shiyi Chen, Wei Xu, Mary Vyas, Katie Bingham, Keyur Patel, Leslie Lilly, Mark Cattral, Nazia Selzner, Elmar Jaeckel, Cynthia Tsien, Aliya Gulamhusein, Gideon M. Hirschfield, Mamatha Bhat Hepatology Communications.2023;[Epub] CrossRef
Cancer Incidence in Living Liver Donors After Donor Hepatectomy Jongman Kim, Jae Heon Kim, Hyun Jung Kim Journal of Korean Medical Science.2023;[Epub] CrossRef
The Effect of Model for End-Stage Liver Disease 3.0 on Disparities between Patients with and without Hepatocellular Carcinoma in Korea Kunhee Kim, Deok-Gie Kim, Jae Geun Lee, Dong Jin Joo, Hye Won Lee Yonsei Medical Journal.2023; 64(11): 647. CrossRef
Pretransplant Functional Status Predicts Postoperative Morbidity and Mortality after Liver Transplantation in Patients with Cirrhosis Myung Ji Goh, Jihye Kim, Won Hyuk Chang, Dong Hyun Sinn, Geum-Yeon Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Jong Man Kim, Wonseok Kang Gut and Liver.2023; 17(5): 786. CrossRef
Successful liver transplantation from a donor with occlusive portal vein thrombosis M. S. Novruzbekov, O. D. Olisov, V. A. Gulyaev, K. N. Lutsyk, B. I. Yaremin, B. I. Kazymov, K. M. Magomedov, A. R. Akhmedov, K. F. Alekberov Transplantologiya. The Russian Journal of Transplantation.2023; 15(3): 334. CrossRef
Evidence-based hyponatremia management in liver disease Ji Young Ryu, Seon Ha Baek, Sejoong Kim Clinical and Molecular Hepatology.2023; 29(4): 924. CrossRef
Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation Ji Won Han, Jong Young Choi, Eun Sun Jung, Ji Hoon Kim, Hee Sun Cho, Jae-Sung Yoo, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Ho Joong Choi, Young Kyoung You World Journal of Gastrointestinal Surgery.2023; 15(12): 2727. CrossRef
Outcomes of living liver donors are worse than those of matched healthy controls Jin Yong Choi, Jae Heon Kim, Jong Man Kim, Hyun Jung Kim, Hyeong Sik Ahn, Jae-Won Joh Journal of Hepatology.2022; 76(3): 628. CrossRef
Changes in the Deceased-Donor Trend in Korea: Establishment of Regional Trauma Centers and KODA Jeong-Moo Lee Journal of Clinical Medicine.2022; 11(5): 1239. CrossRef
Healthy Spouses can be Considered as Living Liver Donors Okjoo Lee, Jong Man Kim, Sang Jin Kim, Jinsoo Rhu, Gyu‐Seong Choi, Jae‐Won Joh World Journal of Surgery.2022; 46(6): 1474. CrossRef
De Novo Intrahepatic Cholangiocarcinoma After Deceased Donor Liver Transplant in an Adult Patient Hyung Hwan Moon, Dong Hoon Shin, Young Il Choi Experimental and Clinical Transplantation.2022; 20(3): 316. CrossRef
Long-Term Outcomes of Laparoscopic Liver Resection for Centrally Located Hepatocellular Carcinoma Hyo Jun Kim, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Yeongsoo Jo, Meeyouong Kang, Yeshong Park, Eunhye Lee Medicina.2022; 58(6): 737. CrossRef
Long-term Clinical Outcomes and Predictive Factors for Living-donor Liver Transplant Recipients With Biliary Strictures Ji Won Han, Jong Young Choi, Soon Kyu Lee, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Young Hoon Choi, In Seok Lee, Jung Suk Oh, Ho Jong Chun, Ho Joong Choi, Young Kyoung You Transplantation.2022; 106(10): 1990. CrossRef
Non-Renal Risk Factors for Chronic Kidney Disease in Liver Recipients with Functionally Intact Kidneys at 1 Month Deok-Gie Kim, Shin Hwang, Jong Man Kim, Je Ho Ryu, Young Kyoung You, Donglak Choi, Bong-Wan Kim, Dong-Sik Kim, Yang Won Nah, Tae-Seok Kim, Jai Young Cho, Geun Hong, Jae Do Yang, Jaryung Han, Suk-Won Suh, Kwan Woo Kim, Yun Kyung Jung, Ju Ik Moon, Jun Young Journal of Clinical Medicine.2022; 11(14): 4203. CrossRef
Evidence of nonsurgical treatment for polycystic liver disease Jeong-Ju Yoo, Hye In Jo, Eun-Ae Jung, Jae Seung Lee, Sang Gyune Kim, Young Seok Kim, Beom Kyung Kim Therapeutic Advances in Chronic Disease.2022;[Epub] CrossRef
Real‐world clinical features, health‐care utilization, and economic burden in decompensated cirrhosis patients: A national database Hankil Lee, Beom Kyung Kim Journal of Gastroenterology and Hepatology.2022; 37(11): 2154. CrossRef
Low-grade hepatocellular carcinoma characteristics, a practical nomogram and risk stratification system: a SEER population-based study Dashuai Yang, Yang Su, Fangrui Zhao, Yong Hu, Kailiang Zhao, Xiangyun Xiong, Mingqiang Zhu, Junpeng Pei, Youming Ding Expert Review of Gastroenterology & Hepatology.2022; 16(11-12): 1115. CrossRef
Low utilization of adult-to-adult LDLT in Western countries despite excellent outcomes: International multicenter analysis of the US, the UK, and Canada Tommy Ivanics, David Wallace, Marco P.A.W. Claasen, Madhukar S. Patel, Rushin Brahmbhatt, Chaya Shwaartz, Andreas Prachalias, Parthi Srinivasan, Wayel Jassem, Nigel Heaton, Mark S. Cattral, Nazia Selzner, Anand Ghanekar, Gabriela Morgenshtern, Neil Mehta, Journal of Hepatology.2022; 77(6): 1607. CrossRef
Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review Sang Jin Kim, Jong Man Kim Clinical and Molecular Hepatology.2022; 28(4): 739. CrossRef
Development and Validation of a Difficulty Scoring System for Laparoscopic Liver Resection to Treat Hepatolithiasis Yeongsoo Jo, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Eunhye Lee, Yeshong Park, MeeYoung Kang, Junghyun Lee Medicina.2022; 58(12): 1847. CrossRef
Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim Diagnostics.2022; 13(1): 3. CrossRef
New Evidence of Oral Branched-Chain Amino Acid Supplementation on the Prognosis of Patients With Advanced Liver Disease Hankil Lee, Jeong-Ju Yoo, Sang Hoon Ahn, Beom Kyung Kim Clinical and Translational Gastroenterology.2022; 13(12): e00542. CrossRef
Extubation in the operating room results in fewer composite mechanical ventilation-related adverse outcomes in patients after liver transplantation: a retrospective cohort study Yan Xu, Yiding Zuo, Li Zhou, Xuechao Hao, Xiao Xiao, Mao Ye, Lulong Bo, Chunling Jiang, Jiayin Yang BMC Anesthesiology.2021;[Epub] CrossRef
Can hepatocellular carcinoma recurrence be prevented after liver transplantation? Jong Man Kim Clinical and Molecular Hepatology.2021; 27(4): 562. CrossRef
Antibody mediated rejection (AMR) after adult ABO-incompatible living donor liver transplantation (ABO-I LDLT) induced hepatic necrosis or diffuse intrahepatic biliary complications, which were related with poor graft and patient survival. Various desensitization protocols have been used to overcome these problems. Since using rituximab, the outcomes of ABO-I LDLT show a similar survival rate to those of ABO-compatible living donor liver transplantation. However, diffuse bile duct complications still occur after ABO-I LDLT. We have reviewed the past and current immune strategies for desensitization and to provide outcomes and ABO incompatibility-related complications in ABO-I LDLT.
Citations
Citations to this article as recorded by
Five decades of clinical ABO-incompatible liver transplantation research: a bibliometric analysis Maiwulanjiang Maimaiti, Alimujiang Mamuti, Yilizhati Azhati, Aliya Tulading, Yun-Fei Zhang, Jing Wu, Abudusalamu Tuersunmaimaiti, Chun-Hui Lv, Gang Yao, Amina Aierken, Tao Li, Tuerganaili Aji, Ying-Mei Shao, Hao Wen, Tuerhongjiang Tuxun International Journal of Surgery.2025; 111(1): 1508. CrossRef
Tailored strategies for emergency ABO-incompatible living donor liver transplantation: a series of three cases Nalini Kanta Ghosh, Kausar Makki, Yogesh Yadav, Tathagata Karan, Piyush Srivastava, Anil Agarwal, Vivek Vij Clinical Transplantation and Research.2025; 39(2): 161. CrossRef
Heterogeneity and plasticity of cholangiocytes in liver injury: a journey from pathophysiology to therapeutic utility Chengtao Lou, Tianchen Lan, Shengjun Xu, Xinhao Hu, Jiarui Li, Ze Xiang, Shengda Lin, Xiaohui Fan, Jian Chen, Xiao Xu Gut.2025; : gutjnl-2025-334763. CrossRef
Immunology demystified: A guide for transplant hepatologists Iva Kosuta, Tomislav Kelava, Ana Ostojic, Vibor Sesa, Anna Mrzljak, Hrvoje Lalic World Journal of Transplantation.2024;[Epub] CrossRef
Impact of Preformed Donor-specific Antibodies in Comparison to ABO Incompatibility in Living Donor Liver Transplantation: A Propensity Score–Matched Analysis Jiyoung Kim, Suk Kyun Hong, Jae-Yoon Kim, Jaewon Lee, Hyun Hwa Choi, Minseob Kim, Youngjin Kim, Su young Hong, Jeong-Moo Lee, YoungRok Choi, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh Transplantation.2024; 108(9): e229. CrossRef
Human umbilical cord mesenchymal stem cells alleviate fatty liver ischemia‐reperfusion injury by activating autophagy through upregulation of IFNγ Chenhao Xu, Xixi Fang, Bei Lu, Yisu Song, Wenzhi Shu, Zhengyang Lu, Renyi Su, Ze Xiang, Xiao Xu, Xuyong Wei Cell Biochemistry and Function.2024;[Epub] CrossRef
Bile duct diffusion-weighted image hyperintensity predicts intrahepatic biliary complications after ABO-incompatible liver transplantation Kyowon Gu, Woo Kyoung Jeong, Dong Ik Cha, Jeong Ah Hwang, Jinsoo Rhu, Jong Man Kim, Gyu-Seong Choi, Sun-Young Baek European Radiology.2024; 35(1): 393. CrossRef
Impact of Baseline Anti-ABO Antibody Titer on Biliary Complications in ABO-Incompatible Living-Donor Liver Transplantation Se-Hyeon Yu, Hye-Sung Jo, Young-Dong Yu, Pyoung-Jae Park, Hyung-Joon Han, Sang-Jin Kim, Syahrul Hadi Kamarulzaman, Dong-Sik Kim Journal of Clinical Medicine.2024; 13(16): 4789. CrossRef
Consecutive disruption of intrahepatic bile ducts after ABO-incompatible living-donor re-liver transplantation: A case report Akihiko Soyama, Baglan Askeyev, Takanobu Hara, Hajime Matsushima, Tomohiko Adachi, Susumu Eguchi International Journal of Surgery Case Reports.2024; 125: 110606. CrossRef
Outcomes of emergency pediatric ABO-incompatible living donor liver transplantation in Korea Sunghyo An, Jongman Kim, Sang Jin Kim, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung Annals of Liver Transplantation.2024; 4(2): 63. CrossRef
The fate of donor‐type ABO blood group antigen expression in liver grafts in ABO‐incompatible adult living donor liver transplantation Moon Young Oh, Haeryoung Kim, Nam‐Joon Yi, Suyoung Hong, Jeong‐Moo Lee, Sola Lee, Suk Kyun Hong, YoungRok Choi, Kwang‐Woong Lee, Kyung‐Suk Suh Journal of Hepato-Biliary-Pancreatic Sciences.2023; 30(7): 871. CrossRef
Strategies for ABO Incompatible Liver Transplantation Shekhar S. Jadaun, Shaleen Agarwal, Subhash Gupta, Sanjiv Saigal Journal of Clinical and Experimental Hepatology.2023; 13(4): 698. CrossRef
Single-dose eculizumab as part of a modified desensitization protocol for ABO-incompatible living donor liver transplantation Mario Spaggiari, Egor Petrochenkov, Giulia Bencini, Sujata Gaitonde, Jamie Benken, Grace Guzman, Jamie Berkes, Ivo Tzvetanov, Enrico Benedetti Liver Transplantation.2023; 29(8): 906. CrossRef
Pretransplant mycophenolate mofetil may be associated with reduced intrahepatic cholangiopathy in ABO-incompatible liver transplantation Jinsoo Rhu, Jong Man Kim, Gyu-seong Choi, Jae-Won Joh Liver Transplantation.2023; 29(8): 849. CrossRef
Advances and innovations in living donor liver transplant techniques, matching and surgical training: Meeting report from the living donor liver transplant consensus conference Mark Sturdevant, Swaytha Ganesh, Benjamin Samstein, Elizabeth C. Verna, Manuel Rodriguez‐Davalos, Vineeta Kumar, Marwan Abouljoud, Oya Andacoglu, Medhat Askar, Dieter Broering, Juliet Emamaullee, Jean C. Emond, Christine E. Haugen, Michelle T. Jesse, Mure Clinical Transplantation.2023;[Epub] CrossRef
Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation Ji Won Han, Jong Young Choi, Eun Sun Jung, Ji Hoon Kim, Hee Sun Cho, Jae-Sung Yoo, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Ho Joong Choi, Young Kyoung You World Journal of Gastrointestinal Surgery.2023; 15(12): 2727. CrossRef
ABO-Incompatible Living Donor Liver Transplant From a Blood Type A2 Donor to a Type B Recipient: A Note of Caution Yogesh Puri, Ashwin Rammohan, Deepti Sachan, Mukul Vij, Mohamed Rela Experimental and Clinical Transplantation.2022; 20(1): 100. CrossRef
Healthy Spouses can be Considered as Living Liver Donors Okjoo Lee, Jong Man Kim, Sang Jin Kim, Jinsoo Rhu, Gyu‐Seong Choi, Jae‐Won Joh World Journal of Surgery.2022; 46(6): 1474. CrossRef
Mesenchymal Stem Cells and Their Small Extracellular Vesicles as Crucial Immunological Efficacy for Hepatic Diseases Yuting Tang, Peipei Wu, Linli Li, Wenrong Xu, Jiajia Jiang Frontiers in Immunology.2022;[Epub] CrossRef
Overcoming high pre-transplant isoagglutinin titers using high-dose intravenous immunoglobulin, salvage plasmapheresis, and booster rituximab without splenectomy in ABO-incompatible living donor liver transplantation: a case report Hyung Hwan Moon Kosin Medical Journal.2022; 37(2): 163. CrossRef
Real‐world clinical features, health‐care utilization, and economic burden in decompensated cirrhosis patients: A national database Hankil Lee, Beom Kyung Kim Journal of Gastroenterology and Hepatology.2022; 37(11): 2154. CrossRef
New Evidence of Oral Branched-Chain Amino Acid Supplementation on the Prognosis of Patients With Advanced Liver Disease Hankil Lee, Jeong-Ju Yoo, Sang Hoon Ahn, Beom Kyung Kim Clinical and Translational Gastroenterology.2022; 13(12): e00542. CrossRef
Fatal intracardiac and pulmonary arterial thromboembolic damage following ABO-incompatible living donor liver transplantation for autoimmune hepatitis Won Kyu Choi, Junghan Kim, Ho Joong Choi, Sang Hyun Hong, Min Suk Chae Medicine.2021; 100(2): e24298. CrossRef
Differences in Bile Microbiology and Antibiotic Resistances between Liver Transplant Recipients and Non-Transplant Patients Eunhye Kang, Suk-Won Suh, Seung Eun Lee, Yoo Shin Choi, Seong-Ho Choi, Bo-Ram Lee, YoungRok Choi, Jaehong Jeong Surgical Infections.2021; 22(7): 741. CrossRef
Impact of Graft Weight Change During Perfusion on Hepatocellular Carcinoma Recurrence After Living Donor Liver Transplantation Jong Man Kim, Young Jae Chung, Sangjin Kim, Jinsoo Rhu, Gyu-Seong Choi, Jae-Won Joh Frontiers in Oncology.2021;[Epub] CrossRef
ABO-incompatible living donor liver transplantation with high preoperative antibody titer: A case report Yoshikatsu Saitoh, Atsushi Fujio, Shigehito Miyagi, Kazuaki Tokodai, Michiaki Unno, Takashi Kamei International Journal of Surgery Case Reports.2021; 85: 106260. CrossRef
ABO Incompatible Liver Transplantation in Children: A 20 Year Experience from Centres in the TransplantChild European Reference Network Małgorzata Markiewicz-Kijewska, Piotr Kaliciński, Juan Torres Canizales, Angelo Di Giorgio, Ulrich Baumann, Carl Jorns, Alastair Baker, Maria Francelina Lopes, Esteban Frauca Remacha, Eduardo Lopez-Granados, Paloma Jara Vega, Maria-Sole Basso, Grzegorz Ko Children.2021; 8(9): 760. CrossRef
The Human Immune Response to Cadaveric and Living Donor Liver Allografts Angus Hann, Daniel-Clement Osei-Bordom, Desley A. H. Neil, Vincenzo Ronca, Suz Warner, M. Thamara P. R. Perera Frontiers in Immunology.2020;[Epub] CrossRef
Comparison of clinical outcomes between ABO-incompatible and ABO-compatible pediatric liver transplantation: a systematic literature review and meta-analysis Zhong-Yu Kang, Wei Liu, Dai-Hong Li Pediatric Surgery International.2020; 36(11): 1353. CrossRef
Characteristics of Immunoglobulin M Type Antibodies of Different Origins from the Immunologic and Clinical Viewpoints and Their Application in Controlling Antibody-Mediated Allograft Rejection Yoshiko Matsuda, Takahisa Hiramitsu, Xiao-kang Li, Takeshi Watanabe Pathogens.2020; 10(1): 4. CrossRef
Healthy Spouses can be Considered as Living Liver Donors Okjoo Lee, Jong Man Kim, Sang Jin Kim, Jinsoo Rhu, Gyu‐Seong Choi, Jae‐Won Joh World Journal of Surgery.2022; 46(6): 1474. CrossRef
Jong Man Kim, Kwang-Woong Lee, Gi-Won Song, Bo-Hyun Jung, Hae Won Lee, Nam-Joon Yi, ChoonHyuck David Kwon, Shin Hwang, Kyung-Suk Suh, Jae-Won Joh, Suk-Koo Lee, Sung-Gyu Lee
Clin Mol Hepatol 2016;22(3):366-371. Published online September 25, 2016
Background/Aims The relationship between patient survival and biopsy-proven acute rejection (BPAR) in liver transplant recipients with hepatitis C remains unclear. The aims of this study were to compare the characteristics of patients with and without BPAR and to identify risk factors for BPAR.
Methods We retrospectively reviewed the records of 169 HCV-RNA-positive patients who underwent LT at three centers.
Results BPAR occurred in 39 (23.1%) of the HCV-RNA-positive recipients after LT. The 1-, 3-, and 5-year survival rates were 92.1%, 90.3%, and 88.5%, respectively, in patients without BPAR, and 75.7%, 63.4%, and 58.9% in patients with BPAR (P<0.001). Multivariate analyses showed that BPAR was associated with the non-use of basiliximab and tacrolimus and the use of cyclosporin in LT recipients with HCV RNA-positive.
Conclusions The results of the present study suggest that the immunosuppression status of HCV-RNA-positive LT recipients should be carefully determined in order to prevent BPAR and to improve patient survival.
Citations
Citations to this article as recorded by
Early use of everolimus improved renal function after adult deceased donor liver transplantation Seohee Lee, Jong Man Kim, Sangjin Kim, Jinsoo Rhu, Gyu-Seong Choi, Jae-Won Joh Korean Journal of Transplantation.2021; 35(1): 8. CrossRef
First
Prev
